FirstWord

The Drug Development Accelerator Fund will help Formation acquire 10 to 15 drug programmes over the next three to five years.

The findings could help refine patient selection and shape the design of future stroke trials.

Rytelo, competes with Bristol Myers Squibb's Reblozyl, is already approved to treat transfusion-dependent anaemia in patients with lower-risk myelodysplastic syndromes.

One-man company Mithril developed a proof-of-principle for a bispecific antibody treatment for a rare muscular dystrophy in less than 18 months by using Claude to manage operations.

Seven of eight products in the pharma's growth portfolio grew by double digits, including Spinraza and Leqembi, as well as Apellis medicines Syfovre and Empaveli.

Detailed efficacy and safety results from the pivotal phase 3 study demonstrate statistically significant serum urate reductions through 12 monthsPozdeutinurad is an investigational, once-daily, highl...

FirstWord will be speaking with a leading expert about detailed Phase III VOLGA data for AstraZeneca's Imfinzi, and how it and other PD-(L)1 inhibitors like Keytruda will be used with Padcev as perioperative treatment for muscle-invasive bladder cancer.

FirstWord spoke with MassGen's Ashwin Ananthakrishnan about Phase II data for Gilead's emvistegrast to treat ulcerative colitis, and how the oral α4β7 integrin inhibitor could affect practice patterns in IBD.

GSK is talking up its broader pipeline, but analysts couldn't get past concerns over the likelihood of success for upcoming readouts from its long-acting HIV therapies.

FirstWord previews a particularly busy month of PDUFA dates, with at least 13 decisions on the docket.